BioMarin reaffirms long-term guidance: ~$4B revenue by 2027, 40% margin from 2026

BIOMARIN PHARMACEUTICAL INC

Reaffirms ~$4B total revenues in 2027.
Non-GAAP operating margin of 40% starting in 2026, growing to low- to mid-40% range.
Targets >$1.25B operating cash flow per year starting in 2027.
Mid-teen CAGR for total revenues through 2034.
Potential treatments for skeletal conditions represent >$5B revenue opportunity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.